Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 29, 2017

DrugPatentWatch Database Preview

Guaifenesin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for guaifenesin and what is the scope of freedom to operate?

Guaifenesin
is the generic ingredient in seven branded drugs marketed by Actavis Labs Fl, Perrigo R And D, Reckitt Benckiser, Mission Pharmacal Co, and Sovereign Pharms, and is included in eight NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Guaifenesin has thirty-six patent family members in nineteen countries.

There are twenty drug master file entries for guaifenesin. Forty-seven suppliers are listed for this compound.

Summary for Generic Name: guaifenesin

Tradenames:7
Patents:4
Applicants:5
NDAs:8
Drug Master File Entries: see list20
Suppliers / Packagers: see list47
Bulk Api Vendors: see list65
Clinical Trials: see list6
Patent Applications: see list4,232
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:guaifenesin at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Reckitt Benckiser
MUCINEX
guaifenesin
TABLET, EXTENDED RELEASE;ORAL021282-002Dec 18, 2002OTCYesYes6,372,252► Subscribe ► Subscribe
Reckitt Benckiser
MUCINEX
guaifenesin
TABLET, EXTENDED RELEASE;ORAL021282-002Dec 18, 2002OTCYesYes7,838,032► SubscribeY ► Subscribe
Reckitt Benckiser
MUCINEX D
guaifenesin; pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL021585-002Jun 22, 2004OTCYesYes7,838,032► SubscribeY ► Subscribe
Perrigo R And D
GUAIFENESIN
guaifenesin
TABLET, EXTENDED RELEASE;ORAL078912-001Nov 23, 2011OTCNoNo► Subscribe► Subscribe
Reckitt Benckiser
MUCINEX D
guaifenesin; pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL021585-002Jun 22, 2004OTCYesYes6,955,821► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Formulary management
  • Uncover prior art in abandoned patent applications and expired patents

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot